For BRVO , there was a significant reduction from week 24 mean BCVA in ranibizumab plus laser versus ranibizumab at week 48 ( -7.5 vs. +2.8 ; P < 0.01 ) and week 96 ( -2.0 vs. +4.8 ; P < 0.03 ) , but not week 144 , and there were no differences in mean CST change from week 24 at weeks 48 , 96 , or 144 .